Nomura Asset Management Co. Ltd. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 46.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 42,876 shares of the medical equipment provider’s stock after selling 37,076 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Hologic were worth $1,833,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Creative Planning boosted its stake in shares of Hologic by 8.2% in the 4th quarter. Creative Planning now owns 15,396 shares of the medical equipment provider’s stock valued at $658,000 after purchasing an additional 1,161 shares during the last quarter. AT Bancorp boosted its stake in shares of Hologic by 2.2% in the 4th quarter. AT Bancorp now owns 62,329 shares of the medical equipment provider’s stock valued at $2,664,000 after purchasing an additional 1,323 shares during the last quarter. Norinchukin Bank The boosted its stake in shares of Hologic by 7.4% in the 3rd quarter. Norinchukin Bank The now owns 20,876 shares of the medical equipment provider’s stock valued at $766,000 after purchasing an additional 1,445 shares during the last quarter. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Hologic by 3.9% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 39,500 shares of the medical equipment provider’s stock valued at $1,449,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Grove Bank & Trust boosted its stake in shares of Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares during the last quarter. Hedge funds and other institutional investors own 97.59% of the company’s stock.
In other Hologic news, Director Charles J. Dockendorff acquired 13,000 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were purchased at an average cost of $38.80 per share, with a total value of $504,400.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Namal Nawana acquired 6,600 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the completion of the purchase, the director now directly owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The disclosure for this purchase can be found here. 0.79% of the stock is owned by corporate insiders.
Hologic, Inc. (HOLX) opened at $38.46 on Friday. The stock has a market cap of $10,640.84, a price-to-earnings ratio of 18.77, a P/E/G ratio of 1.74 and a beta of 0.84. Hologic, Inc. has a 12 month low of $35.33 and a 12 month high of $46.80. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. Hologic’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 earnings per share. analysts predict that Hologic, Inc. will post 2.25 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2018/03/17/nomura-asset-management-co-ltd-sells-37076-shares-of-hologic-inc-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.